Material and Method: The cross-sectional study of Alzheimer patients who had been taking ChEIs for at least six months (ChEI+) or had never been on any ChEIs (ChEI-) were enrolled from the Memory Clinic, Ramathibodi hospital between September 1, 2014 and February 28, 2015. All of these patients were evaluated with Mini-Mental Status Exam (MMSE) for cognitive function, Neuropsychiatric Inventory-Questionnaire (NPI-Q) for BPSD, and psychotropic dosage used.

Results: Fifty-one Alzheimer patients were enrolled, 31 patients in the ChEI+ group and 20 patients in the ChEI- group. Mean and SD of MMSEs in ChEI+ and ChEI- were 13.6±1.2 and 11.75±1.4, respectively (p-value = 0.33). The Mean and SD of NPI scores in ChEI+ and ChEI- were 15.68±14.31 and 19.5±20.1, respectively (p-value = 0.43). Patients in ChEI+ had tend to had a lower depression severity score (p = 0.10) and lower burden from aggression/agitation (p = 0.08). The differences were not statistically significant. Mean highest dosages per day (olanzapine equivalence) in the ChEI+ and ChEI- were 1.6 mg and 3.1 mg, respectively (p-value = 0.07).

Conclusion: The total off NPI score between the ChEI+ and ChEI- groups were not different, but there were report the trends toward lower depression severity score, aggression/agitation distress score, and antipsychotic dosages use in the ChEI+.

Keywords: Alzheimer’s disease, Behavioral and psychological symptoms, Cholinesterase inhibitors, Depression, Aggression, Antipsychotics